Natixis Advisors LLC Boosts Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Natixis Advisors LLC raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0% in the third quarter, Holdings Channel.com reports. The fund owned 43,174 shares of the company’s stock after acquiring an additional 3,206 shares during the quarter. Natixis Advisors LLC’s holdings in IDEXX Laboratories were worth $21,812,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Eads & Heald Wealth Management raised its stake in shares of IDEXX Laboratories by 0.8% in the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock valued at $1,309,000 after acquiring an additional 22 shares in the last quarter. LRI Investments LLC raised its position in IDEXX Laboratories by 21.7% in the 2nd quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after purchasing an additional 23 shares in the last quarter. Mather Group LLC. boosted its stake in shares of IDEXX Laboratories by 3.9% in the 3rd quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after buying an additional 23 shares during the period. Sovereign Financial Group Inc. grew its position in shares of IDEXX Laboratories by 5.1% during the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company’s stock worth $237,000 after buying an additional 23 shares in the last quarter. Finally, Angeles Wealth Management LLC increased its stake in shares of IDEXX Laboratories by 2.4% during the third quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company’s stock worth $545,000 after buying an additional 25 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $419.83 on Tuesday. The stock has a market cap of $34.38 billion, a P/E ratio of 40.49, a P/E/G ratio of 3.67 and a beta of 1.36. IDEXX Laboratories, Inc. has a twelve month low of $404.74 and a twelve month high of $583.39. The stock has a 50 day moving average of $467.11 and a two-hundred day moving average of $482.44. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter in the prior year, the firm earned $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on IDXX shares. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research report on Thursday, October 10th. BTIG Research initiated coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Finally, JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $552.38.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.